Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium

Zai Lab Q3 2026 Earnings Call Transcript

Zai Lab (NASDAQ:ZLAB) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For

8-K filing — Zai Lab Ltd (ZLAB)

Filed: 2026-11-05 AccNo: 0001628280-26-070517 Size: 397 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Zai Lab Announces $250 Million Private Placement

Zai Lab Limited has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing to raise approximately $250 million.

Zai Lab To Present First Phase 1/1b Data On Atopic Dermatitis Candidate ZL-1503 In Healthy Volunteers On November 13

Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript

Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings

The Insider Report: The Leaders Have Taken Off

Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the